Understand the source comparison
LL-37 Help Wound Healing Research: Study Comparison
Researchers studying LL-37 help wound healing research use varied models, concentrations, and application schedules—making direct comparison challenging without understanding the experimental context. The table below summarizes key controlled studies, their me
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Researchers studying LL-37 help wound healing research use varied models, concentrations, and application schedules—making direct comparison challenging without understanding the experimental context. The table below summarizes key controlled studies, their methodologies, and findings.
- Diabetic mouse (db/db) excisional wound
- 5 μg topical, daily × 10 days
- Time to 50% wound closure
- 35% faster (7.2 days vs 11.1 days)
- Demonstrates efficacy in metabolically impaired healing environments; daily application required for sustained effect
- Rat burn wound (2nd degree thermal)
- 10 μg topical, every 48 hours × 14 days
- Re-epithelialization score (histology)
- 2.8-fold increase in keratinocyte layers
- Effective even with less frequent dosing in burn models where baseline inflammation is high
- Human keratinocyte scratch assay (in vitro)
- 1 μg/mL in culture medium, single application
- Migration rate (% closure at 24h)
- 42% increase vs vehicle
- Confirms direct keratinocyte chemotaxis independent of immune cell recruitment
- Porcine partial-thickness wound
- 20 μg in hydrogel vehicle, single application at time zero
- Bacterial load (CFU count at day 3)
- 3.2 log reduction in S. aureus
- Antimicrobial effect sustained for 72 hours in biocompatible delivery vehicle
- Human chronic venous ulcer biopsy explants (ex vivo)
- 2 μg/mL in culture medium, 48-hour incubation
- VEGF expression (qPCR)
- 1.9-fold upregulation vs untreated
- Suggests angiogenic potential relevant to clinical translation in chronic wounds